Per Editor: Li Zedong
On December 8, the official website of the State Drug Administration released the news that tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd. approved the registration application of Tengsheng Huachuang Pharmaceutical Technology (Beijing) Co., Ltd. for the combination treatment of new coronavirus neutralization antibody combination treatment drugs ampavirinumab injection (BRII-196) and romisvir monoclonal antibody injection (BRII-198).
It is reported that this is the first approved independent intellectual property rights in China to neutralize antibody combination therapy drugs for the new coronavirus.
According to CCTV Finance and Economics reported on December 13, experts introduced the role of the approved new coronavirus neutralizing antibody combination treatment drug "amphavir monoclonal antibody injection and romimavir monoclonal antibody injection". But at present, the pace of mutation of the new crown virus has not stopped, can the drug resist the mutated virus? Will there be any side effects after using the drug?
Zhong Nanshan, an academician of the Chinese Academy of Engineering, presided over the phase II clinical study of the drug in China, and led the demonstration and promotion of the emergency treatment of the drug in China, further verifying the safety and efficacy of the drug in Chinese patients.
Zhong Nanshan, an academician of the Chinese Academy of Engineering, said: "BRII-196, 198 (amphavir monoclonal antibody and romisvir maclizumab) antibodies are very effective for the treatment of patients with a relatively large viral load, and so far it should be said that this is the most effective." It is very valuable for China to be able to produce a developed drug of its own design on the antibody. The drug itself has also been screened out by a lot of antibodies, so I think the promotion of the drug in the world is very valuable. ”
On December 12, Tengsheng Bo Pharmaceutical issued an announcement, and the data showed that the approved drugs maintained the effectiveness of "Omicron" and other widely concerned new coronavirus variants, including Alpha, Beta, Gamma, Delta, Delta+, etc. Zhang Qi, an assistant researcher at Tsinghua University's School of Medicine who participated in the research and development, said that the mutation of the virus may still exist, but researchers have prepared.
According to the announcement, the experimental detection data of in vitro chimeric viruses in independent laboratories show that the "Omikejong" variant strain is easily neutralized by the combination therapy of amphavir monoclonal antibody and romidavir monoclonal antibody. Although the activity of ampavirub against the "Omikejunn" variant was significantly reduced, romizumab was not affected by the "Omikejung" variant. Thus the combination therapy maintained neutralizing activity against the "Omi kerong" variant.
On the news side, on the 13th, Tengsheng Bo Pharmaceutical-B reported HK$37 per share, down 14.15%, and the current total market value is HK$26.65 billion.
Daily Economic News comprehensive CCTV Finance, Xinhua Finance, public information reports
Daily economic news